These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Hepatitis caused by various derivatives of erythromycin]. Funck-Brentano C; Pessayre D; Benhamou JP Gastroenterol Clin Biol; 1983 Apr; 7(4):362-9. PubMed ID: 6347792 [No Abstract] [Full Text] [Related]
4. [Cholestatic hepatitis caused by erythromycin estolate]. García Monzón C; Noguerado A; Hidalgo S; Escudero V Rev Clin Esp; 1985 Nov; 177(8):420-1. PubMed ID: 3836470 [No Abstract] [Full Text] [Related]
5. Erythromycin estolate-induced hepatitis. Ultrastructural study of liver. Gafter U; Mandel EM; Weiss S; Djaldetti M N Y State J Med; 1979 Jan; 79(1):87-9. PubMed ID: 282477 [No Abstract] [Full Text] [Related]
6. FDA begins proceedings to remove erythromycin estolate from market. FDA Drug Bull; 1979 Nov; 9(5):26-7. PubMed ID: 510836 [No Abstract] [Full Text] [Related]
7. Risk-benefit equation for erythromycin estolate. LeBel M Am J Hosp Pharm; 1980 Feb; 37(2):176, 180. PubMed ID: 7361788 [No Abstract] [Full Text] [Related]
8. Erythromycin propionate and estolate. Farre M Lancet; 1988 Jul; 2(8601):45. PubMed ID: 2898648 [No Abstract] [Full Text] [Related]
9. Selection of an oral erythromycin product. Fraser DG Am J Hosp Pharm; 1980 Sep; 37(9):1199-205. PubMed ID: 6998290 [TBL] [Abstract][Full Text] [Related]
10. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate. Keeffe EB; Reis TC; Berland JE Dig Dis Sci; 1982 Aug; 27(8):701-4. PubMed ID: 6980110 [TBL] [Abstract][Full Text] [Related]
11. Ilosone update. Culp ER Am Fam Physician; 1980 Apr; 21(4):23. PubMed ID: 7377065 [No Abstract] [Full Text] [Related]
13. A prospective study on the incidence of liver function abnormalities in children receiving erythromycin estolate, erythromycin ethylsuccinate or penicillin V for treatment of pneumonia. Ginsburg CM Pediatr Infect Dis; 1986; 5(1):151-3. PubMed ID: 3080735 [No Abstract] [Full Text] [Related]
14. [Controlled study of the liver-protective effect of cycloxilic acid in a form of iatrogenic liver disease]. Neuman M; Fluteau G Clin Ter; 1978 Nov; 87(3):243-64. PubMed ID: 380876 [No Abstract] [Full Text] [Related]
16. Cholestatic hepatitis caused by esters of erythromycin and oleandomycin. 1962. Gilbert FI Hawaii Med J; 1995 Jun; 54(6):603-5. PubMed ID: 7642362 [No Abstract] [Full Text] [Related]
19. [On the article of J. Buchanec and V. Kdrajnák: Lesions of the liver during therapy with erythromycin in 3 children]. Rouzica M; Filipová K Cesk Pediatr; 1975 Jan; 30(1-2):71. PubMed ID: 1132045 [No Abstract] [Full Text] [Related]